BIO.News Newsletter

A new report explains why Mexico’s ban on GM corn is a lose-lose for Mexico and the U.S., and some want to use the Bayh-Dole Act to achieve “backdoor” drug price controls, which would amount to a “frontal assault” on R&D. (701 words, 3 minutes, 30 seconds)

D.C.’s in recess, but there’s a lot happening. We have a look at BIO’s recent comments on FDA’s clinical trial diversity guidance, a long-awaited USDA nominee, and why Accelerated Approval is under political attack. (772 words, 3 minutes, 51 seconds)

Ending the week on a high note: COVID vaccines prevented nearly 20 million deaths in 2021 alone, says a new study. And from bird flu to stopping salmonella outbreaks, CRISPR technology is improving the health of chickens and the risk to humans. (667 words, 3 minutes, 20 seconds)

Lots of news today from Capitol Hill on PBMs, ARPA-H, and a new insulin bill—plus, BIO’s comments to OSTP on sustainable chemistry. (725 words, 3 minutes, 37 seconds)

A small biotech tells the FTC how M&As can help advance innovation for patients—and a rise in bird flu, including in the U.S., tells us that it’s time to advance gene editing and One Health. (591 words, 2 minutes, 57 seconds)

Back to work—and we take a deeper dive into why we don’t need the COVID vaccine waiver. Meanwhile, extreme heat is killing cows in Kansas—but the FDA’s already given the green light to a biotech solution for cattle welfare. (695 words, 3 minutes, 28 seconds)

On Friday, the WTO agreed to a waiver of COVID vaccine intellectual property protections—here’s what we know. And while it’s a federal holiday in DC (and for BIO) for Juneteenth, we want to take a moment to look at why this day is an important reminder of the need for diversity, equity, and inclusion in health care and our industry. (733 words, 3 minutes, 39 seconds)

FDA Commissioner Dr. Robert M. Califf joined the final day of BIO International Convention—here’s what he said about Accelerated Approval, misinformation, and the things the agency does other than drugs. (776 words, 3 minutes, 52 seconds)

Day 3 of the BIO International Convention put a focus on Accelerated Approval—including its value and why it matters for patients. We also heard from patient advocates including the great Venus Williams about why patients’ stories are so important. (724 words, 3 minutes, 37 seconds)

We have new reports on VC funding for biotech and the value of federally funded research—plus, what happened during the Senate HELP Committee’s markup of FDA user fee legislation and more news from Day 2 of BIO International Convention. (842 words, 4 minutes, 12 seconds)